These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897 [TBL] [Abstract][Full Text] [Related]
5. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Callebaut C; Stepan G; Tian Y; Miller MD Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. Duwal S; Schütte C; von Kleist M PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148 [TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V. Margot N; Ram R; Abram M; Haubrich R; Callebaut C Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104 [TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548 [TBL] [Abstract][Full Text] [Related]
9. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons. Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. Tao X; Lu Y; Zhou Y; Zhang L; Chen Y Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012 [TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. Custodio JM; Fordyce M; Garner W; Vimal M; Ling KH; Kearney BP; Ramanathan S Antimicrob Agents Chemother; 2016 Sep; 60(9):5135-40. PubMed ID: 27216057 [TBL] [Abstract][Full Text] [Related]
13. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677 [TBL] [Abstract][Full Text] [Related]
14. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R; AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154 [TBL] [Abstract][Full Text] [Related]
15. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539 [TBL] [Abstract][Full Text] [Related]
16. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805 [TBL] [Abstract][Full Text] [Related]
17. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335 [TBL] [Abstract][Full Text] [Related]
18. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). De Clercq E Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890 [TBL] [Abstract][Full Text] [Related]
19. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459 [TBL] [Abstract][Full Text] [Related]
20. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Margot NA; Liu Y; Miller MD; Callebaut C Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]